Cargando…
Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study
OBJECTIVES: This study investigated the effects of dose step-down in patients with rheumatoid arthritis (RA) who achieved sustained disease control with baricitinib 4 mg once a day. METHODS: Patients who completed a baricitinib phase 3 study could enter a long-term extension (LTE). In the LTE, patie...
Autores principales: | Takeuchi, Tsutomu, Genovese, Mark C, Haraoui, Boulos, Li, Zhanguo, Xie, Li, Klar, Rena, Pinto-Correia, Ana, Otawa, Susan, Lopez-Romero, Pedro, de la Torre, Inmaculada, Macias, William, Rooney, Terence P, Smolen, Josef S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6352419/ https://www.ncbi.nlm.nih.gov/pubmed/30194275 http://dx.doi.org/10.1136/annrheumdis-2018-213271 |
Ejemplares similares
-
Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis
por: Harigai, Masayoshi, et al.
Publicado: (2020) -
Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis
por: Taylor, Peter C., et al.
Publicado: (2019) -
Baricitinib further enhances disease-modifying effects by uncoupling the link between disease activity and joint structural progression in patients with rheumatoid arthritis
por: Lopez-Romero, Pedro, et al.
Publicado: (2022) -
Effects of baricitinib on radiographic progression of structural joint damage at 1 year in patients with rheumatoid arthritis and an inadequate response to conventional synthetic disease-modifying antirheumatic drugs
por: van der Heijde, Desirée, et al.
Publicado: (2018) -
Safety and efficacy of baricitinib in elderly patients with rheumatoid arthritis
por: Fleischmann, Roy, et al.
Publicado: (2017)